Foreign news sources quoted people familiar with the matter as saying that AI drug developersInsilicon Smart(Insilico Medicine) plans to go public in Hong Kong, and has appointed CICC and Morgan Stanley to carry out related work. Inco Intelligence expects to raise about 200 million US dollars in capital.

Insilicon SmartEstablished in 2014, it mainly provides artificial intelligence software for pharmaceutical and biotech companies. An application for listing in the US was reported at the end of 2021.

Insilicon SmartAfter several rounds of financing, its investors include Yao Ming Kant, Huaping Investment, Temasek Temasek, Qingchi Capital, Sequoia China, Fosun Pharmaceuticals, Shidao Capital, Lilly Asia Fund, Innovation Factory, Aobo Capital, BV Baidu Venture Capital, CPE Yuanfeng, Prosperity7 Ventures, Bohai Huamei, B Capital Group, Qiming Venture Capital, Bold Capital Partners, Deerfield Management, Pavilion Capital, WS Investment, Formic Ventures, Mirae Asset Global Investments, Sage Partners Reichi Capital, President International Development Corporation, F-Prime Capital, Juvenescence, Deep Knowledge Ventures etc.